Resources Contact Us Home
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Image Number 13 for United States Patent #8119616.

The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a .beta.-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

  Recently Added Patents
Management of memory array with magnetic random access memory (MRAM)
Distributive data capture
Area efficient through-hole connections
Resist underlayer film forming composition for lithography, containing aromatic fused ring-containing resin
Intake parameter-calculating device for internal combustion engine and method of calculating intake parameter
Link establishment in a wireless communication environment
Image sensor pixels with junction gate photodiodes
  Randomly Featured Patents
Low temperature sintered ceramic capacitor with high DC breakdown voltage, and method of manufacture
Phased array system to produce, steer and stabilize non-circularly-symmetric beams
Syringe assembly
Two wire capacitance transmitter
Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors
Migration engine for use in a logical namespace of a storage system environment
Method and system for detecting one or more gases or gas mixtures and/or for measuring the concentration of one or more gases or gas mixtures
Isolated nucleic acid molecules which encode renal cancer specific antigens, and uses thereof
Apparatus and method for ventilation of animal enclosures
Arrangement for testing battery while under load and charging